Topic:

M&A

Latest Headlines

Latest Headlines

We warned you, Depomed: Horizon pushes down hostile path

Horizon Pharma is done playing nice in its quest to nab Depomed. Now that its target has dismissed its updated buyout bid, it's charging full-force into hostile pursuit.

UPDATED: Shire chief Ornskov bets $300M on another eye drug bolt-on buyout

Shire CEO Flemming Ornskov is spending $300 million of his cache of cash on a new ophthalmology buyout. Ornskov has pulled the trigger on a deal to snap up Foresight Biotherapeutics, adding a new bolt-on group with plans to take an eye drug into Phase III.

PRA bolsters eClinical suite with tuck-in acquisition

PRA plans to integrate the acquired assets into its nascent Predictivv platform and in doing so continue its attempts to use IT to stand out from the CRO crowd.

Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO says

Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during a Senate committee hearing on Thursday.

ResMed acquires China's Curative Medical to get bigger in sleep disorder devices

ResMed increased its focus on sleep disorder devices by acquiring China's Curative Medical for an undisclosed sum, in an attempt to gain a foothold in a fast-growing market.

Abbott moves more into mitral valve med tech, to buy startup for $250M and options another

Abbott will buy two mitral valve replacement startups, moving it even further into med tech after a series of high-profile deals last year. It obviously sees the sector as a way for it to plan for long-term growth--since its innovative biopharma candidates went with AbbVie when the companies split in early 2013.

Depomed pooh-poohs Horizon's new bid in latest rejection

Last week, Horizon raised its buyout offer for California's Depomed in order to spur the drugmaker into coming to the bargaining table. But it looks like it'll have to go with Plan B.

Analysts: Mylan won't land Perrigo, even with Teva out of the way

Teva's $40.5 billion deal to buy Allergan's generics business ended its pursuit of Mylan and left its rival the chance to snap up its own hostile target, Perrigo. But the way some analysts see it, things won't necessarily go that way.

With new cash on its way, it's back to buying for deal-happy Allergan, CEO says

On Monday, Allergan agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. But CEO Brent Saunders is already thinking about future buys.

Mallinckrodt to sell contrast business to French imaging player Guerbet for $270M

German specialty pharma Mallinckrodt has opted to sell off its contrast media and delivery systems business to Paris-based Guerbet for about $270 million as part of a strategic review of its business. The business has had declining revenues, but generates substantial cash and will mean a big step up for Guerbet.